Kim Smith, ViiV R&D chief

With com­peti­tors cir­cling, Vi­iV wins an­oth­er la­bel up­date for long-act­ing HIV in­jectable Cabe­nu­va

Just over a year af­ter it was ini­tial­ly ap­proved, GSK’s HIV unit Vi­iV Health­care has found yet an­oth­er way to make Cabe­nu­va’s la­bel even more at­trac­tive.

Cabe­nu­va con­sists of two ex­tend­ed-re­lease in­jecta­bles: cabote­gravir, which is de­vel­oped by Vi­iV, and rilpivirine from J&J’s Janssen which is al­so mar­ket­ed in­di­vid­u­al­ly un­der the brand names Edu­rant and Rekam­bys. Pre­vi­ous­ly, pa­tients start­ing out on the long-act­ing HIV treat­ment were re­quired to first take cabote­gravir and rilpivirine by mouth for one month to as­sess their tol­er­a­bil­i­ty of the med­i­cines be­fore mov­ing on to in­jec­tions.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.